|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
Chains A, B:
E.C.2.5.1.58
- Protein farnesyltransferase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Farnesyl diphosphate + protein-cysteine = S-farnesyl protein + diphosphate
|
 |
 |
 |
 |
 |
Farnesyl diphosphate
Bound ligand (Het Group name = )
matches with 50.00% similarity
|
+
|
protein-cysteine
|
=
|
S-farnesyl protein
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Cofactor:
|
 |
Magnesium; Zinc
|
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chain A:
E.C.2.5.1.59
- Protein geranylgeranyltransferase type I.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Geranylgeranyl diphosphate + protein-cysteine = S-geranylgeranyl- protein + diphosphate
|
 |
 |
 |
 |
 |
Geranylgeranyl diphosphate
Bound ligand (Het Group name = )
matches with 43.00% similarity
|
+
|
protein-cysteine
|
=
|
S-geranylgeranyl- protein
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Cofactor:
|
 |
Zinc
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
protein complex
|
4 terms
|
 |
|
Biological process
|
response to inorganic substance
|
15 terms
|
 |
|
Biochemical function
|
catalytic activity
|
14 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Mol Biol
343:417-433
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.
|
|
T.S.Reid,
K.L.Terry,
P.J.Casey,
L.S.Beese.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Post-translational modifications are essential for the proper function of many
proteins in the cell. The attachment of an isoprenoid lipid (a process termed
prenylation) by protein farnesyltransferase (FTase) or geranylgeranyltransferase
type I (GGTase-I) is essential for the function of many signal transduction
proteins involved in growth, differentiation, and oncogenesis. FTase and
GGTase-I (also called the CaaX prenyltransferases) recognize protein substrates
with a C-terminal tetrapeptide recognition motif called the Ca1a2X box. These
enzymes possess distinct but overlapping protein substrate specificity that is
determined primarily by the sequence identity of the Ca1a2X motif. To determine
how the identity of the Ca1a2X motif residues and sequence upstream of this
motif affect substrate binding, we have solved crystal structures of FTase and
GGTase-I complexed with a total of eight cognate and cross-reactive substrate
peptides, including those derived from the C termini of the oncoproteins
K-Ras4B, H-Ras and TC21. These structures suggest that all peptide substrates
adopt a common binding mode in the FTase and GGTase-I active site. Unexpectedly,
while the X residue of the Ca1a2X motif binds in the same location for all
GGTase-I substrates, the X residue of FTase substrates can bind in one of two
different sites. Together, these structures outline a series of rules that
govern substrate peptide selectivity; these rules were utilized to classify
known protein substrates of CaaX prenyltransferases and to generate a list of
hypothetical substrates within the human genome.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1. Chemical structures of isoprenoid diphosphates
and non-hydrolyzable analogs.
|
 |
Figure 4.
Figure 4. Comparison of the a[2] binding site in FTase and
GGTase-I. Superposition of FTase and GGTase-I shows residues
that interact with the a[2] residue of the Ca[1]a[2]X motif.
Regions of the FTase ternary complex forming the a[2] binding
site (enzyme residues Trp102b, Trp106b and Tyr361b and isoprene
3) are colored red. Corresponding regions of the GGTase-I
ternary complex (enzyme residues Thr49b, Phe53b and Leu321b,
isoprenes 3 and 4, and substrate peptide X residue) are colored
blue. Portions of the FPP and GGPP analogs (gray) and of the
CVIM (pink) and CVIL (light blue) peptides not forming the a[2]
site are shown.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(2004,
343,
417-433)
copyright 2004.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.R.Philips
(2011).
The perplexing case of the geranylgeranyl transferase-deficient mouse.
|
| |
J Clin Invest, 121,
510-513.
|
 |
|
|
|
|
 |
A.J.DeGraw,
M.J.Keiser,
J.D.Ochocki,
B.K.Shoichet,
and
M.D.Distefano
(2010).
Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.
|
| |
J Med Chem, 53,
2464-2471.
|
 |
|
|
|
|
 |
A.J.Krzysiak,
A.V.Aditya,
J.L.Hougland,
C.A.Fierke,
and
R.A.Gibbs
(2010).
Synthesis and screening of a CaaL peptide library versus FTase reveals a surprising number of substrates.
|
| |
Bioorg Med Chem Lett, 20,
767-770.
|
 |
|
|
|
|
 |
B.S.Davies,
R.H.Barnes,
Y.Tu,
S.Ren,
D.A.Andres,
H.P.Spielmann,
J.Lammerding,
Y.Wang,
S.G.Young,
and
L.G.Fong
(2010).
An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria.
|
| |
Hum Mol Genet, 19,
2682-2694.
|
 |
|
|
|
|
 |
J.L.Hougland,
K.A.Hicks,
H.L.Hartman,
R.A.Kelly,
T.J.Watt,
and
C.A.Fierke
(2010).
Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities.
|
| |
J Mol Biol, 395,
176-190.
|
 |
|
|
|
|
 |
J.M.Fres,
S.Müller,
and
G.J.Praefcke
(2010).
Purification of the CaaX-modified, dynamin-related large GTPase hGBP1 by coexpression with farnesyltransferase.
|
| |
J Lipid Res, 51,
2454-2459.
|
 |
|
|
|
|
 |
R.Lee,
S.Y.Chang,
H.Trinh,
Y.Tu,
A.C.White,
B.S.Davies,
M.O.Bergo,
L.G.Fong,
W.E.Lowry,
and
S.G.Young
(2010).
Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes.
|
| |
Hum Mol Genet, 19,
1603-1617.
|
 |
|
|
|
|
 |
U.T.Nguyen,
R.S.Goody,
and
K.Alexandrov
(2010).
Understanding and exploiting protein prenyltransferases.
|
| |
Chembiochem, 11,
1194-1201.
|
 |
|
|
|
|
 |
Y.S.Oh,
D.G.Kim,
G.Kim,
E.C.Choi,
B.K.Kennedy,
Y.Suh,
B.J.Park,
and
S.Kim
(2010).
Downregulation of lamin A by tumor suppressor AIMP3/p18 leads to a progeroid phenotype in mice.
|
| |
Aging Cell, 9,
810-822.
|
 |
|
|
|
|
 |
F.Calvo,
and
P.Crespo
(2009).
Structural and spatial determinants regulating TC21 activation by RasGRF family nucleotide exchange factors.
|
| |
Mol Biol Cell, 20,
4289-4302.
|
 |
|
|
|
|
 |
J.L.Donelson,
H.B.Hodges-Loaiza,
B.S.Henriksen,
C.A.Hrycyna,
and
R.A.Gibbs
(2009).
Solid-phase synthesis of prenylcysteine analogs.
|
| |
J Org Chem, 74,
2975-2981.
|
 |
|
|
|
|
 |
J.L.Hougland,
C.L.Lamphear,
S.A.Scott,
R.A.Gibbs,
and
C.A.Fierke
(2009).
Context-dependent substrate recognition by protein farnesyltransferase.
|
| |
Biochemistry, 48,
1691-1701.
|
 |
|
|
|
|
 |
L.N.Chan,
C.Hart,
L.Guo,
T.Nyberg,
B.S.Davies,
L.G.Fong,
S.G.Young,
B.J.Agnew,
and
F.Tamanoi
(2009).
A novel approach to tag and identify geranylgeranylated proteins.
|
| |
Electrophoresis, 30,
3598-3606.
|
 |
|
|
|
|
 |
M.A.Hast,
S.Fletcher,
C.G.Cummings,
E.E.Pusateri,
M.A.Blaskovich,
K.Rivas,
M.H.Gelb,
W.C.Van Voorhis,
S.M.Sebti,
A.D.Hamilton,
and
L.S.Beese
(2009).
Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase.
|
| |
Chem Biol, 16,
181-192.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.Rucktäschel,
S.Thoms,
V.Sidorovitch,
A.Halbach,
M.Pechlivanis,
R.Volkmer,
K.Alexandrov,
J.Kuhlmann,
H.Rottensteiner,
and
R.Erdmann
(2009).
Farnesylation of pex19p is required for its structural integrity and function in peroxisome biogenesis.
|
| |
J Biol Chem, 284,
20885-20896.
|
 |
|
|
|
|
 |
Y.K.Peterson,
X.S.Wang,
P.J.Casey,
and
A.Tropsha
(2009).
Discovery of geranylgeranyltransferase-I inhibitors with novel scaffolds by the means of quantitative structure-activity relationship modeling, virtual screening, and experimental validation.
|
| |
J Med Chem, 52,
4210-4220.
|
 |
|
|
|
|
 |
A.J.DeGraw,
M.A.Hast,
J.Xu,
D.Mullen,
L.S.Beese,
G.Barany,
and
M.D.Distefano
(2008).
Caged protein prenyltransferase substrates: tools for understanding protein prenylation.
|
| |
Chem Biol Drug Des, 72,
171-181.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.S.Weiss,
H.S.Kruth,
H.Kuivaniemi,
G.Tromp,
J.Karkera,
S.Mahurkar,
W.Lisch,
W.J.Dupps,
P.S.White,
R.S.Winters,
C.Kim,
C.J.Rapuano,
J.Sutphin,
J.Reidy,
F.R.Hu,
d.a. .W.Lu,
N.Ebenezer,
and
M.L.Nickerson
(2008).
Genetic analysis of 14 families with Schnyder crystalline corneal dystrophy reveals clues to UBIAD1 protein function.
|
| |
Am J Med Genet A, 146,
271-283.
|
 |
|
|
|
|
 |
K.Yokoyama,
J.R.Gillespie,
W.C.Van Voorhis,
F.S.Buckner,
and
M.H.Gelb
(2008).
Protein geranylgeranyltransferase-I of Trypanosoma cruzi.
|
| |
Mol Biochem Parasitol, 157,
32-43.
|
 |
|
|
|
|
 |
M.A.Hast,
and
L.S.Beese
(2008).
Structure of Protein Geranylgeranyltransferase-I from the Human Pathogen Candida albicans Complexed with a Lipid Substrate.
|
| |
J Biol Chem, 283,
31933-31940.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Maynor,
S.A.Scott,
E.L.Rickert,
and
R.A.Gibbs
(2008).
Synthesis and evaluation of 3- and 7-substituted geranylgeranyl pyrophosphate analogs.
|
| |
Bioorg Med Chem Lett, 18,
1889-1892.
|
 |
|
|
|
|
 |
P.J.Roberts,
N.Mitin,
P.J.Keller,
E.J.Chenette,
J.P.Madigan,
R.O.Currin,
A.D.Cox,
O.Wilson,
P.Kirschmeier,
and
C.J.Der
(2008).
Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification.
|
| |
J Biol Chem, 283,
25150-25163.
|
 |
|
|
|
|
 |
T.Subramanian,
S.Liu,
J.M.Troutman,
D.A.Andres,
and
H.P.Spielmann
(2008).
Protein farnesyltransferase-catalyzed isoprenoid transfer to peptide depends on lipid size and shape, not hydrophobicity.
|
| |
Chembiochem, 9,
2872-2882.
|
 |
|
|
|
|
 |
A.J.Krzysiak,
D.S.Rawat,
S.A.Scott,
J.E.Pais,
M.Handley,
M.L.Harrison,
C.A.Fierke,
and
R.A.Gibbs
(2007).
Combinatorial modulation of protein prenylation.
|
| |
ACS Chem Biol, 2,
385-389.
|
 |
|
|
|
|
 |
A.J.Krzysiak,
S.A.Scott,
K.A.Hicks,
C.A.Fierke,
and
R.A.Gibbs
(2007).
Evaluation of protein farnesyltransferase substrate specificity using synthetic peptide libraries.
|
| |
Bioorg Med Chem Lett, 17,
5548-5551.
|
 |
|
|
|
|
 |
A.K.Sjogren,
K.M.Andersson,
M.Liu,
B.A.Cutts,
C.Karlsson,
A.M.Wahlstrom,
M.Dalin,
C.Weinbaum,
P.J.Casey,
A.Tarkowski,
B.Swolin,
S.G.Young,
and
M.O.Bergo
(2007).
GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer.
|
| |
J Clin Invest, 117,
1294-1304.
|
 |
|
|
|
|
 |
A.Shutes,
C.Onesto,
V.Picard,
B.Leblond,
F.Schweighoffer,
and
C.J.Der
(2007).
Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.
|
| |
J Biol Chem, 282,
35666-35678.
|
 |
|
|
|
|
 |
G.Cui,
and
K.M.Merz
(2007).
Computational studies of the farnesyltransferase ternary complex part II: the conformational activation of farnesyldiphosphate.
|
| |
Biochemistry, 46,
12375-12381.
|
 |
|
|
|
|
 |
M.Ikeda,
and
N.Kato
(2007).
Modulation of host metabolism as a target of new antivirals.
|
| |
Adv Drug Deliv Rev, 59,
1277-1289.
|
 |
|
|
|
|
 |
M.R.Philips,
and
A.D.Cox
(2007).
Geranylgeranyltransferase I as a target for anti-cancer drugs.
|
| |
J Clin Invest, 117,
1223-1225.
|
 |
|
|
|
|
 |
P.A.Konstantinopoulos,
M.V.Karamouzis,
and
A.G.Papavassiliou
(2007).
Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.
|
| |
Nat Rev Drug Discov, 6,
541-555.
|
 |
|
|
|
|
 |
P.J.Roberts,
and
C.J.Der
(2007).
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
|
| |
Oncogene, 26,
3291-3310.
|
 |
|
|
|
|
 |
S.Lenevich,
J.Xu,
A.Hosokawa,
C.J.Cramer,
and
M.D.Distefano
(2007).
Transition state analysis of model and enzymatic prenylation reactions.
|
| |
J Am Chem Soc, 129,
5796-5797.
|
 |
|
|
|
|
 |
T.Suzuki,
M.Ito,
T.Ezure,
M.Shikata,
E.Ando,
T.Utsumi,
S.Tsunasawa,
and
O.Nishimura
(2007).
Protein prenylation in an insect cell-free protein synthesis system and identification of products by mass spectrometry.
|
| |
Proteomics, 7,
1942-1950.
|
 |
|
|
|
|
 |
B.Couderc,
M.Penary,
M.Tohfe,
A.Pradines,
A.Casteignau,
D.Berg,
and
G.Favre
(2006).
Reversible inactivation of the transcriptional function of P53 protein by farnesylation.
|
| |
BMC Biotechnol, 6,
26.
|
 |
|
|
|
|
 |
D.Santini,
M.Caraglia,
B.Vincenzi,
I.Holen,
S.Scarpa,
A.Budillon,
and
G.Tonini
(2006).
Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates.
|
| |
Nat Clin Pract Oncol, 3,
325-338.
|
 |
|
|
|
|
 |
E.Rung,
P.A.Friberg,
C.Bergh,
and
H.Billig
(2006).
Depletion of substrates for protein prenylation increases apoptosis in human periovulatory granulosa cells.
|
| |
Mol Reprod Dev, 73,
1277-1283.
|
 |
|
|
|
|
 |
L.J.Plummer,
E.R.Hildebrandt,
S.B.Porter,
V.A.Rogers,
J.McCracken,
and
W.K.Schmidt
(2006).
Mutational analysis of the ras converting enzyme reveals a requirement for glutamate and histidine residues.
|
| |
J Biol Chem, 281,
4596-4605.
|
 |
|
|
|
|
 |
M.H.Gelb,
L.Brunsveld,
C.A.Hrycyna,
S.Michaelis,
F.Tamanoi,
W.C.Van Voorhis,
and
H.Waldmann
(2006).
Therapeutic intervention based on protein prenylation and associated modifications.
|
| |
Nat Chem Biol, 2,
518-528.
|
 |
|
|
|
|
 |
Y.K.Peterson,
P.Kelly,
C.A.Weinbaum,
and
P.J.Casey
(2006).
A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity.
|
| |
J Biol Chem, 281,
12445-12450.
|
 |
|
|
|
|
 |
A.M.Winter-Vann,
and
P.J.Casey
(2005).
Post-prenylation-processing enzymes as new targets in oncogenesis.
|
| |
Nat Rev Cancer, 5,
405-412.
|
 |
|
|
|
|
 |
D.E.Nelson,
D.P.Virok,
H.Wood,
C.Roshick,
R.M.Johnson,
W.M.Whitmire,
D.D.Crane,
O.Steele-Mortimer,
L.Kari,
G.McClarty,
and
H.D.Caldwell
(2005).
Chlamydial IFN-gamma immune evasion is linked to host infection tropism.
|
| |
Proc Natl Acad Sci U S A, 102,
10658-10663.
|
 |
|
|
|
|
 |
N.Ferri,
R.Paoletti,
and
A.Corsini
(2005).
Lipid-modified proteins as biomarkers for cardiovascular disease: a review.
|
| |
Biomarkers, 10,
219-237.
|
 |
|
|
|
|
 |
N.Mijimolle,
J.Velasco,
P.Dubus,
C.Guerra,
C.A.Weinbaum,
P.J.Casey,
V.Campuzano,
and
M.Barbacid
(2005).
Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development.
|
| |
Cancer Cell, 7,
313-324.
|
 |
|
|
|
|
 |
S.M.Sebti
(2005).
Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.
|
| |
Cancer Cell, 7,
297-300.
|
 |
|
|
|
|
 |
S.Maurer-Stroh,
and
F.Eisenhaber
(2005).
Refinement and prediction of protein prenylation motifs.
|
| |
Genome Biol, 6,
R55.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|